Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence

150 HCC patients with tumor >5cm, multiple tumor and who cannot accept R0 resection will be randomized divided into 3 groups. Group A (50 cases) will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected. Group B (50 cases) will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin. Group C (50 cases) will be the controlled one which will not be implanted any chemotherapeutic drugs. All patients will accepted TACE 30 days after liver resection. We will follow up all patients until they are dead or missed connected. Related adverse reaction will be recorded. Total survival time (TST) and disease free survival time (DFST) will be calculated too. At the end of the study we will compare the difference of adverse reaction, complication, TST and DFST between the 3 groups. According to the result we will estimate these drugs' antitumor effect and safety.

Inclusion criteria

• tumor >5cm;
• multiple tumor located in one liver lobe;
• margin of tumor is not clear;
• cutting edge to tumor <1cm;
• portal vein branch invasion;
• without extra-liver metastasis;
• patient's liver function and condition is able to accept hepatectomy.

Exclusion criteria

• single tumor <=5cm;
• multiple tumor located more than in one liver lobe;
• margin of tumor is clear;
• cutting edge to tumor >=1cm;
• portal vein stem invasion
• extra-liver metastasis;
• patient's liver function and condition cannot accept hepatectomy.